AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30611255 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical gingivitis
Number of subjects: 1452
Study 30611255 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding on probing (BOP)
Number of subjects: 1452
Study 30611255 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing depth (PD)
Number of subjects: 1452
Study 30611255 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival recession
Number of subjects: 1452
Study 30611255 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1452
Study 30611255 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal stature
Number of subjects: 1452
Study 30611255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost barrier to dental care
Number of subjects: 1452
Study 30611293 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-HOBA acetate (up to 825 mg)
Number of subjects: 18
Study 30611582 — intervention group
Group type: EXPERIMENTAL
Intervention: ENROUTE transcarotid neuroprotection system (NPS) during transcarotid artery revascularization (TCAR)
Number of subjects: 165
Study 30611659 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-gene Oncotype DX Genomic Prostate Score (GPS) assay
Number of subjects: 1200
Study 30611839 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy delivering 22.5 Gy in 3 fractions of 7.5 Gy
Number of subjects: 200
Study 30612558 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223, 55 kBq/kg intravenously, every 4 weeks for up to 6 cycles
Number of subjects: 708
Study 30612568 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oxaliplatin-based or irinotecan-based chemotherapy
Number of subjects: 264
Study 30612602 — intervention group
Group type: EXPERIMENTAL
Intervention: Long visit tests including walking test, blood tests, determination of diffusion, pulse oximetry, bioimpedance, and low radiation CT for participants with COPD.
Number of subjects: 3581
Study 30612602 — intervention group
Group type: EXPERIMENTAL
Intervention: New imaging data, biomarkers, and information on new exposures such as electronic cigarettes and environmental pollution.
Number of subjects: 3581
Study 30612602 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometric results and other factors associated with COPD.
Number of subjects: 3581
Study 30612710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg, intravenous, once every 3 weeks)
Number of subjects: 92
Study 30612825 — intervention group
Group type: EXPERIMENTAL
Intervention: GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE)
Number of subjects: 13
Study 30612959 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic powder (TC-325/Hemospray) applied as monotherapy in 13 bleeding sites (25%)
Number of subjects: 50
Study 30612959 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic powder (TC-325/Hemospray) applied as combination therapy in 22 bleeding sites (42.3%)
Number of subjects: 50
Study 30612959 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic powder (TC-325/Hemospray) applied as rescue therapy in 17 bleeding sites (32.7%)
Number of subjects: 50
Study 30612959 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic powder (TC-325/Hemospray)
Number of subjects: 50
Study 30613413 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 464
Study 30613413 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 464
Study 30613413 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 464
Study 30613427 — intervention group
Group type: EXPERIMENTAL
Intervention: SASA! community mobilisation intervention
Number of subjects: 0
Study 30613427 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30613416 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant primary mitral regurgitation (MR)
Number of subjects: 46
Study 30613416 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 46
Study 30613416 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of EDPVR
Number of subjects: 46
Study 30614187 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating total testosterone (TT) > 14.76 nmol/L
Number of subjects: 248
Study 30614187 — intervention group
Group type: COMPARATOR
Intervention: Circulating total testosterone (TT) ≤ 14.76 nmol/L
Number of subjects: 248
Study 30614320 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2000
Study 30614320 — intervention group
Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 2000
Study 30614531 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus 5-fluorouracil/leucovorin (5-FU/LV) maintenance
Number of subjects: 0
Study 30614531 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV ± bevacizumab maintenance
Number of subjects: 0
Study 30614939 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide therapy (1 mg BID for 8 weeks)
Number of subjects: 17
Study 30614939 — intervention group
Group type: COMPARATOR
Intervention: N/A (Control group: GERD patients)
Number of subjects: 17
Study 30615047 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic measures of sympathetic tone (resting heart rate, blood pressure, resting heart rate variability, postexercise heart rate recovery and blood pressure)
Number of subjects: 24
Study 30615047 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic measures of sympathetic tone (Chapman points and viscerosomatic reflexes)
Number of subjects: 24
Study 30615047 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic structural examination
Number of subjects: 24
Study 30615169 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral PrEP
Number of subjects: 226
Study 30615169 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centered care coordination (C4)
Number of subjects: 226
Study 30615169 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline STI diagnosis
Number of subjects: 226
Study 30615302 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly elevated mean PAP (21-24 mm Hg)
Number of subjects: 112
Study 30615302 — intervention group
Group type: COMPARATOR
Intervention: Normal mean PAP (≤20 mm Hg)
Number of subjects: 112
Study 30615623 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
Number of subjects: 163
Study 30615623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of EBUS-TBNA
Number of subjects: 163
Study 30616360 — intervention group
Group type: EXPERIMENTAL
Intervention: RV-pulmonary arterial coupling (Ees/Ea)
Number of subjects: 42
Study 30616360 — intervention group
Group type: EXPERIMENTAL
Intervention: End-systolic volume
Number of subjects: 42
Study 30616360 — intervention group
Group type: EXPERIMENTAL
Intervention: End-diastolic volume/body surface area (BSA)
Number of subjects: 42
Study 30616360 — intervention group
Group type: EXPERIMENTAL
Intervention: RV ejection fraction (EF)
Number of subjects: 42
Study 30616360 — intervention group
Group type: EXPERIMENTAL
Intervention: End-diastolic elastance (Eed)
Number of subjects: 42
Study 30616578 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free Teens Programme (2-day-1-night training camp, creative activities, award presentation ceremony)
Number of subjects: 856
Study 30616617 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care for drug sensitive and multidrug-resistant pulmonary TB
Number of subjects: 1600
Study 30616617 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized quality of life questionnaire and adapted WHO's generic patient cost instrument
Number of subjects: 1600
Study 30616705 — intervention group
Group type: EXPERIMENTAL
Intervention: High early-childhood BI
Number of subjects: 87
Study 30616705 — intervention group
Group type: EXPERIMENTAL
Intervention: Low early-childhood BI
Number of subjects: 87
Study 30616737 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 4755
Study 30616737 — intervention group
Group type: COMPARATOR
Intervention: Influenza-positive patients
Number of subjects: 4755
Study 30616737 — intervention group
Group type: COMPARATOR
Intervention: Risk factors for mortality in influenza-positive patients
Number of subjects: 4755
Study 30616998 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (100 mg/day) plus Quercetin (1250 mg/day), three-days/week over three-weeks
Number of subjects: 14
Study 30617104 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based automated detection of nocturnal cough and sleep quality assessment
Number of subjects: 94
Study 30617104 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Control Test
Number of subjects: 94
Study 30617104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index
Number of subjects: 94
Study 30617198 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept (0.6-1.25 mg/kg)
Number of subjects: 64
Study 30617198 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept (0.8 to 1.25 mg/kg)
Number of subjects: 64
Study 30617563 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 10
Study 30617611 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow ECCO
Number of subjects: 20
Study 30617611 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined system with membrane lung (0.32 m)
Number of subjects: 20
Study 30617997 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful reperfusion (defined as modified Thrombolysis in Cerebral Infarction grade 2b/3)
Number of subjects: 193
Study 30617997 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful reperfusion
Number of subjects: 193
Study 30617997 — intervention group
Group type: COMPARATOR
Intervention: Mechanical thrombectomy in patients with NIHSS < 8
Number of subjects: 193
Study 30618063 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling using the communication tool about diet
Number of subjects: 12
Study 30618179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg once every 3 weeks for 2 years or until disease progression/unacceptable toxicity
Number of subjects: 38
Study 30618593 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30618764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Combination of Chinese Herbal Medicine
Number of subjects: 0
Study 30618764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30618820 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS) training and individualized nutritional support
Number of subjects: 31
Study 30618820 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not provided)
Number of subjects: 31
Study 30618929 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Number of subjects: 0
Study 30618929 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30619077 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) for gait rehabilitation, details on dosage and duration not available
Number of subjects: 0
Study 30619080 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 51
Study 30619351 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (CTLA-4-Ig)
Number of subjects: 0
Study 30619351 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockade of OX40L
Number of subjects: 0
Study 30619502 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in cereal fiber and coffee, free of red meat
Number of subjects: 0
Study 30619502 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (independent of fiber, coffee, or meat)
Number of subjects: 0
Study 30619615 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-particle curcumin 90 mg once daily for 6 months
Number of subjects: 500
Study 30619615 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 6 months
Number of subjects: 500
Study 30620669 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 121
Study 30621586 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Concept Mapping (GCM)
Number of subjects: 141
Study 30621586 — intervention group
Group type: COMPARATOR
Intervention: Interviews
Number of subjects: 141
Study 30621615 — intervention group
Group type: EXPERIMENTAL
Intervention: Option B+ (antiretroviral therapy throughout life)
Number of subjects: 157
Study 30621615 — intervention group
Group type: COMPARATOR
Intervention: Option A (standard of care during pregnancy and breastfeeding)
Number of subjects: 157
Study 30621615 — intervention group
Group type: EXPERIMENTAL
Intervention: Option B+
Number of subjects: 157
Study 30621698 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab
Number of subjects: 0
Study 30621699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid fentanyl test strips (FTS); participants received ten FTS for personal use after training on how to use them.
Number of subjects: 93
Study 30621699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid fentanyl test strips (FTS); participants reported giving FTS to friends at high risk for fentanyl exposure.
Number of subjects: 93
Study 30621712 — intervention group
Group type: EXPERIMENTAL
Intervention: Living donor liver transplantation with two-stage hepatectomy
Number of subjects: 3
Study 30621712 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 3
Study 30621729 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuss bar removal
Number of subjects: 9
Study 30621829 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy metrics on POD 0 (16:00-23:00) and POD 0 night (23:00-POD 1, 06:00)
Number of subjects: 84
Study 30621829 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative wrist actigraphy metrics
Number of subjects: 84
Study 30621976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotus valve (Boston Scientific)
Number of subjects: 1014
Study 30621976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotus valve with Depth Guard
Number of subjects: 1014
Study 30621982 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 222
Study 30621982 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 222
Study 30622089 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-body blue light device (wavelengths: 415 nm and 450 nm)
Number of subjects: 150
Study 30622089 — intervention group
Group type: COMPARATOR
Intervention: Placebo irradiation
Number of subjects: 150
Study 30622093 — intervention group
Group type: EXPERIMENTAL
Intervention: ESRA-C intervention
Number of subjects: 370
Study 30622093 — intervention group
Group type: COMPARATOR
Intervention: Control (electronic symptom assessment and participant symptom reports alone)
Number of subjects: 370
Study 30622093 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who received clinician recommendations
Number of subjects: 370
Study 30622093 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who did not follow clinician recommendations
Number of subjects: 370
Study 30622093 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 370
Study 30622094 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) with Wildflowers app
Number of subjects: 86
Study 30622094 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training with game 2048
Number of subjects: 86
Study 30622180 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 5
Study 30622321 — intervention group
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T cells
Number of subjects: 5
Study 30622463 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification (ABM) training for 14 days
Number of subjects: 134
Study 30622463 — intervention group
Group type: COMPARATOR
Intervention: Placebo training for 14 days
Number of subjects: 134
Study 30622502 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30622509 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and reminder-based intervention for adherence to direct oral anticoagulant treatment
Number of subjects: 0
Study 30622509 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 30622667 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban (administered continuously for 48 hours)
Number of subjects: 56
Study 30622716 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 270
Study 30622728 — intervention group
Group type: EXPERIMENTAL
Intervention: Arts-based intervention
Number of subjects: 30
Study 30622728 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 30
Study 30622733 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual reloading exercises
Number of subjects: 44
Study 30622733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 44
Study 30622737 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept+MTX
Number of subjects: 405
Study 30622737 — intervention group
Group type: COMPARATOR
Intervention: Placebo+MTX
Number of subjects: 405
Study 30622936 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil supplementation during breastfeeding
Number of subjects: 0
Study 30622936 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 0
Study 30623229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal nab-paclitaxel (IP) at a dose of 112.5 mg/m²
Number of subjects: 6
Study 30623229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal nab-paclitaxel (IP) at doses 35-175 mg/m²
Number of subjects: 6
Study 30623229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal nab-paclitaxel (IP)
Number of subjects: 6
Study 30623276 — intervention group
Group type: EXPERIMENTAL
Intervention: ontuxizumab 2-12 mg/kg weekly (part 1)
Number of subjects: 46
Study 30623276 — intervention group
Group type: EXPERIMENTAL
Intervention: ontuxizumab 4 or 8 mg/kg weekly, or 12 mg/kg biweekly (part 2)
Number of subjects: 46
Study 30623279 — intervention group
Group type: EXPERIMENTAL
Intervention: CorTempR™ Wireless Ingestible Temperature Sensor
Number of subjects: 30
Study 30623279 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M Bair Hugger™ Temperature Monitoring System Zero Flux Thermometer
Number of subjects: 30
Study 30623279 — intervention group
Group type: COMPARATOR
Intervention: oesophageal probe
Number of subjects: 30
Study 30623351 — intervention group
Group type: EXPERIMENTAL
Intervention: EchoPAC (GE Healthcare)
Number of subjects: 156
Study 30623351 — intervention group
Group type: EXPERIMENTAL
Intervention: QLAB (Philips Healthcare)
Number of subjects: 156
Study 30623351 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EchoPAC and QLAB
Number of subjects: 156
Study 30623414 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy (accelerometer worn for up to 7 days)
Number of subjects: 66
Study 30623414 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 66
Study 30624149 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone group (MG, N = 18; 500 mg in the CPB priming)
Number of subjects: 36
Study 30624149 — intervention group
Group type: COMPARATOR
Intervention: Non-methylprednisolone group (NMG, N = 18)
Number of subjects: 36
Study 30624149 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone group (MG)
Number of subjects: 36
Study 30624546 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib (100 mg twice daily)
Number of subjects: 70
Study 30624546 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 70
Study 30624587 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-enriched diet (FADSDIET) for 4 weeks
Number of subjects: 62
Study 30624603 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g fish oil/d containing 1.9-2.2 g eicosapentaenoic acid and 1.1 g docosahexanoic acid for 6 weeks
Number of subjects: 208
Study 30624668 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin methanesulfonate 6 million IU (MIU) loading dose followed by 3 MIU every 8 hours
Number of subjects: 8
Study 30624668 — intervention group
Group type: EXPERIMENTAL
Intervention: PIRRT
Number of subjects: 8
Study 30624668 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin methanesulfonate
Number of subjects: 8
Study 30624677 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected participants
Number of subjects: 141
Study 30624677 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected participants
Number of subjects: 141
Study 30624677 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 141
Study 30624677 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected men
Number of subjects: 141
Study 30624677 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected men
Number of subjects: 141
Study 30624677 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV group
Number of subjects: 141
Study 30624827 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved Informed Consent Process (IICP) involving viewing a video and participating in extended group discussions.
Number of subjects: 112
Study 30624827 — intervention group
Group type: COMPARATOR
Intervention: HIV disclosed status
Number of subjects: 112
Study 30624987 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with fibromuscular dysplasia
Number of subjects: 150
Study 30624987 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive patients
Number of subjects: 150
Study 30624987 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 150
Study 30625462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 60 mg
Number of subjects: 32
Study 30625501 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient portal invitation to visit a LCS interactive Web site
Number of subjects: 1000
Study 30625501 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Web site for screening eligibility
Number of subjects: 1000
Study 30625501 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest computed tomography
Number of subjects: 1000